Abnormal MoCA and normal range MMSE scores in Parkinson disease without dementia: Cognitive and neurochemical correlates

Parkinsonism and Related Disorders

Volumn 20, Issue 10, 2014, Pages 1076-1080

  Chou, Kelvin L ^a   Lenhart, Adrienne ^b   Koeppe, Robert A ^a   Bohnen, Nicolaas I ^a,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VAAAHS   (United States)

Author keywords

Assessment of cognitive disorders dementia; MCI (mild cognitive impairment); PD (Parkinson disease); PET (positron emission tomography)

Indexed keywords

CARBIDOPA PLUS LEVODOPA; DIHYDROTETRABENAZINE MONOAMINERGIC C 11; DOPAMINE RECEPTOR STIMULATING AGENT; METHYL 4 PIPERIDINYL PROPIONATE ACETYLCHOLINESTERASE C 11; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 4-HYDROXYPHENETHYLGUANIDINE; ACETYLCHOLINESTERASE; DIHYDROTETRABENAZINE; GUANIDINE DERIVATIVE; SLC18A2 PROTEIN, HUMAN; TETRABENAZINE; VESICULAR MONOAMINE TRANSPORTER;

ADULT; AGED; ARTICLE; BRAIN FUNCTION; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CRITERION VARIABLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE DURATION; DISEASE SEVERITY; DOPAMINERGIC TRANSMISSION; FEMALE; HOEHN AND YAHR SCALE; HUMAN; IMAGE ANALYSIS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MONTREAL COGNITIVE ASSESSMENT; MOVEMENT DISORDER SOCIETY TASK FORCE; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; VERY ELDERLY; ANALOGS AND DERIVATIVES; BRAIN; COGNITION DISORDERS; COMPLICATION; MENTAL HEALTH; METABOLISM; SCINTISCANNING;

ACETYLCHOLINESTERASE; AGED; AGED, 80 AND OVER; BRAIN; COGNITION DISORDERS; FEMALE; GUANIDINES; HUMANS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; TETRABENAZINE; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84908122709     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2014.07.008     Document Type: Article

References (31)

1. Muslimovic D., Post B., Speelman J.D., Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 2005 Oct 25, 65(8):1239-1245.
2. Litvan I., Aarsland D., Adler C.H., Goldman J.G., Kulisevsky J., Mollenhauer B., et al. MDS task force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord 2011 Aug 15, 26(10):1814-1824.
3. Hely M.A., Reid W.G., Adena M.A., Halliday G.M., Morris J.G. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008 Apr 30, 23(6):837-844.
4. Nasreddine Z.S., Phillips N.A., Bedirian V., Charbonneau S., Whitehead V., Collin I., et al. The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. JAm Geriatr Soc 2005 Apr, 53(4):695-699.
5. Folstein M.F., Folstein S.E., McHugh P.R. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. JPsychiatr Res 1975, 12:189-198.
6. Chou K.L., Amick M.M., Brandt J., Camicioli R., Frei K., Gitelman D., et al. Arecommended scale for cognitive screening in clinical trials of Parkinson's disease. Mov Disord 2010 Nov 15, 25(15):2501-2507.
7. Dalrymple-Alford J.C., MacAskill M.R., Nakas C.T., Livingston L., Graham C., Crucian G.P., et al. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology 2010 Nov 9, 75(19):1717-1725.
8. Lessig S., Nie D., Xu R., Corey-Bloom J. Changes on brief cognitive instruments over time in Parkinson's disease. Mov Disord 2012 Aug, 27(9):1125-1128.
9. Litvan I., Goldman J.G., Troster A.I., Schmand B.A., Weintraub D., Petersen R.C., et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: movement disorder society task force guidelines. Mov Disord 2012 Mar, 27(3):349-356.
10. Jokinen P., Bruck A., Aalto S., Forsback S., Parkkola R., Rinne J.O. Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat Disord 2009 Feb, 15(2):88-93.
11. Bruck A., Portin R., Lindell A., Laihinen A., Bergman J., Haaparanta M., et al. Positron emission tomography shows that impaired frontal lobe functioning in Parkinson's disease is related to dopaminergic hypofunction in the caudate nucleus. Neurosci Lett 2001, 311:81-84.
12. Bohnen N.I., Kaufer D.I., Ivanco L.S., Lopresti B., Koeppe R.A., Davis J.G., et al. Cortical cholinergic function is more severely affected in Parkinsonian dementia than in Alzheimer disease: an invivo positron emission tomographic study. Arch Neurol 2003 Dec, 60(12):1745-1748.
13. Bohnen N.I., Mueller M.L.T.M., Kotagal V., Koeppe R.A., Kilbourn M.R., Gilman S., et al. Heterogeneity of cholinergic denervation in Parkinson disease. JCereb Blood Flow Metab 2012, 32(8):1609-1617.
14. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. JNeurol Neurosurg Psychiatr 1992 Mar, 55(3):181-184.
15. Lawton M.P., Brody E.M. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969, Autumn;9(3):179-186.
16. 11C]PMP) for invivo measurements of acetylcholinesterase activity. Nucl Med Biol 1998, 25:751-754.
17. 11C]dihydrotetrabenazine (DTBZ). Nucl Med Biol 1997 Feb, 24(2):197-199.
18. 11)C]MP4A using a high-radioactivity brain region that represents an integrated input function for measurement of cerebral acetylcholinesterase activity without arterial blood sampling. JCereb Blood Flow Metab 2001 Nov, 21(11):1354-1366.
19. 11C]dihydrotetrabenazine. JCereb Blood Flow Metab 1999 Dec, 19(12):1376-1384.
20. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology 1967 May, 17(5):427-442.
21. O'Bryant S.E., Humphreys J.D., Smith G.E., Ivnik R.J., Graff-Radford N.R., Petersen R.C., et al. Detecting dementia with the mini-mental state examination in highly educated individuals. Arch Neurol 2008 Jul, 65(7):963-967.
22. Nazem S., Siderowf A.D., Duda J.E., Have T.T., Colcher A., Horn S.S., et al. Montreal cognitive assessment performance in patients with Parkinson's disease with "normal" global cognition according to mini-mental state examination score. JAm Geriatr Soc 2009 Feb, 57(2):304-308.
23. Stuss D.T., Alexander M.P. Executive functions and the frontal lobes: a conceptual view. Psychol Res 2000, 63(3-4):289-298.
24. Marras C., Armstrong M.J., Meaney C.A., Fox S., Rothberg B., Reginold W., et al. Measuring mild cognitive impairment in patients with Parkinson's disease. Mov Disord 2013 May, 28(5):626-633.
25. Broeders M., de Bie R.M., Velseboer D.C., Speelman J.D., Muslimovic D., Schmand B. Evolution of mild cognitive impairment in Parkinson disease. Neurology 2013 Jul 23, 81(4):346-352.
26. Churchyard A., Lees A. The relationship between dementia and direct involvement of the hippocampus and amygdala in Parkinson's disease. Neurology 1997, 49:1570-1576.
27. Jellinger K.A. The morphological basis of mental dysfunction in Parkinson's disease. JNeurol Sci 2006 Oct 25, 248(1-2):167-172.
28. Alexander G.E., Crutcher M.D. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 1990 Jul, 13(7):266-271.
29. Hilker R., Thomas A.V., Klein J.C., Weisenbach S., Kalbe E., Burghaus L., et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005 Dec 13, 65(11):1716-1722.
30. Williams-Gray C.H., Foltynie T., Brayne C.E., Robbins T.W., Barker R.A. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 2007 Jul, 130(Pt 7):1787-1798.
31. Zarei M., Ibarretxe-Bilbao N., Compta Y., Hough M., Junque C., Bargallo N., et al. Cortical thinning is associated with disease stages and dementia in Parkinson's disease. JNeurol Neurosurg Psychiatr 2013 Aug, 84(8):875-882.